Article

Lecia V. Sequist Provides an Overview of T790M Mutations in NSCLC

Author(s):

Lecia V. Sequist

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene. T790M is the primary cause of treatment resistance in EGFR-positive patients with non-small cell lung cancer (NSCLC).

Related Videos
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Image of woman with dark hair, smiling.
Image of woman with brown hair.
Image of man with grey hair.
Image of woman with black hair.
Image of a smiling woman with brown hair.
Image of a woman with short brown hair, wearing glasses.
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Related Content
Image of Jace.
December 24th 2024

Jace Yawnick of Jace Beats Cancer on the ‘Roller Coaster’ of Life in Remission

Alex Biese
After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of a woman with brown hair smiling.
December 23rd 2024

Ways to Organize Medical Bills During Cancer

Ashley Chan
Utilizing tools such as spreadsheet trackers can make a big difference when organizing cancer-related medical bills and noting out-of-pocket maximums.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of a smiling woman with brown hair.
December 20th 2024

How to Self Advocate When Insurance Says No to Cancer Treatment Coverage

Ashley Chan
When insurance denies coverage of cancer treatment, patients with cancer don’t need to take no for an answer, an expert explained.
"FDA" text.
Published: December 18th 2024 | Updated: December 19th 2024

FDA Approves Ensacove for ALK-Positive NSCLC

Alex Biese
The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.